Iqbal, R., Kramer, G. M., Frings, V., Smit, E. F., Hoekstra, O. S., & Boellaard, R. (2018). Validation of [(18)F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor. EJNMMI Res.
Styl ChicagoIqbal, R., G. M. Kramer, V. Frings, E. F. Smit, O. S. Hoekstra, a R. Boellaard. "Validation of [(18)F]FLT As a Perfusion-independent Imaging Biomarker of Tumour Response in EGFR-mutated NSCLC Patients Undergoing Treatment With an EGFR Tyrosine Kinase Inhibitor." EJNMMI Res 2018.
Citace podle MLAIqbal, R., et al. "Validation of [(18)F]FLT As a Perfusion-independent Imaging Biomarker of Tumour Response in EGFR-mutated NSCLC Patients Undergoing Treatment With an EGFR Tyrosine Kinase Inhibitor." EJNMMI Res 2018.